[go: up one dir, main page]

EP0397798A4 - Therapeutic use of anti-t cell immunotoxin for autoimmune diseases - Google Patents

Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Info

Publication number
EP0397798A4
EP0397798A4 EP19890902872 EP89902872A EP0397798A4 EP 0397798 A4 EP0397798 A4 EP 0397798A4 EP 19890902872 EP19890902872 EP 19890902872 EP 89902872 A EP89902872 A EP 89902872A EP 0397798 A4 EP0397798 A4 EP 0397798A4
Authority
EP
European Patent Office
Prior art keywords
autoimmune diseases
therapeutic use
cell immunotoxin
immunotoxin
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890902872
Other versions
EP0397798A1 (en
Inventor
Patrick J. Scannon
Richard C. Harmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Royalty Corp
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of EP0397798A1 publication Critical patent/EP0397798A1/en
Publication of EP0397798A4 publication Critical patent/EP0397798A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP19890902872 1988-02-03 1989-02-03 Therapeutic use of anti-t cell immunotoxin for autoimmune diseases Withdrawn EP0397798A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15174488A 1988-02-03 1988-02-03
US151744 1988-02-03

Publications (2)

Publication Number Publication Date
EP0397798A1 EP0397798A1 (en) 1990-11-22
EP0397798A4 true EP0397798A4 (en) 1991-10-30

Family

ID=22540082

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890902872 Withdrawn EP0397798A4 (en) 1988-02-03 1989-02-03 Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Country Status (5)

Country Link
EP (1) EP0397798A4 (en)
JP (1) JPH03503887A (en)
AU (1) AU633251B2 (en)
DK (1) DK184890A (en)
WO (1) WO1989006968A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000583A1 (en) * 1987-07-17 1989-01-26 Xoma Corporation Improved immunotoxin therapies utilizing purified ricin a-chain species
DE68924354T2 (en) * 1988-12-13 1996-02-22 Univ Florida METHOD AND COMPOSITIONS FOR EARLY DETECTING TREATMENT OF INSULIN-DEPENDENT DIABETES MELLITUS (IDDM).
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
ATE138196T1 (en) * 1989-03-06 1996-06-15 Univ California TESTING FOR AND TREATMENT OF AUTOIMMUNE DISEASES
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
IL98932A0 (en) * 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
IT1249051B (en) * 1991-02-26 1995-02-11 Italfarmaco Spa IMMUNOTOXIN FROM ANTI-CD5 MONOCLONAL ANTIBODIES
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
DE69233204T2 (en) * 1991-12-13 2004-07-15 Xoma Corp., Berkeley METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
US6632928B1 (en) 1997-03-05 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
AU3654499A (en) * 1998-04-22 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
KR20200094181A (en) 2017-11-29 2020-08-06 마젠타 테라퓨틱스 인코포레이티드 Compositions and methods for depleting CD5+ cells
EP3980034A4 (en) * 2019-06-05 2024-02-28 Heidelberg Pharma Research GmbH T-cell depleting therapies
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0232447A1 (en) * 1986-02-13 1987-08-19 Xoma Corporation Lectin immunotoxins
EP0256471A2 (en) * 1986-08-15 1988-02-24 Xoma Corporation Cytotoxic conjugates for cancer therapy
WO1989001340A1 (en) * 1987-08-17 1989-02-23 The United States Of America, As Represented By Th Method for treating malignancy and autoimmune disorders in humans
WO1989005816A1 (en) * 1987-12-15 1989-06-29 Protein Design Labs, Inc. Cellular toxic conjugates
WO1989006967A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0232447A1 (en) * 1986-02-13 1987-08-19 Xoma Corporation Lectin immunotoxins
EP0256471A2 (en) * 1986-08-15 1988-02-24 Xoma Corporation Cytotoxic conjugates for cancer therapy
WO1989001340A1 (en) * 1987-08-17 1989-02-23 The United States Of America, As Represented By Th Method for treating malignancy and autoimmune disorders in humans
WO1989005816A1 (en) * 1987-12-15 1989-06-29 Protein Design Labs, Inc. Cellular toxic conjugates
WO1989006967A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO8906968A1 *
STN File Server & File CA & CHEMICAL ABSTRACTS, Vol. 101, No. 11, Abstract No. 88567c, Columbus, Ohio, US; N.A. KERNAN et al.: "Specific inhibition of in vitro lymphocyte transformation by an anti-pan T-cell (gp67) ricin A chain immunotoxin", & J. Immunol., 133(1), 137-146, Abstract. *

Also Published As

Publication number Publication date
DK184890A (en) 1990-10-03
EP0397798A1 (en) 1990-11-22
DK184890D0 (en) 1990-08-02
JPH03503887A (en) 1991-08-29
AU633251B2 (en) 1993-01-28
AU3215789A (en) 1989-08-25
WO1989006968A1 (en) 1989-08-10

Similar Documents

Publication Publication Date Title
EP0397798A4 (en) Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
GB2231265B (en) Therapeutic use of serotonin-antagonists
GB8813175D0 (en) Medicinal/therapeutic pack
EP0799617A3 (en) Therapeutic agent for neurological diseases
GR862352B (en) Collection of human body discharge
ZA898605B (en) Compositions for topical treatment of skin diseases
AU2690684A (en) Methods and pharmaceutical compositions for the treatment of hyperplastic diseases of the skin
EP0212501A3 (en) Therapeutic agent for treating hematopoietic diseases
EP0310386A3 (en) Therapeutic agents
HUP9802834A3 (en) Preparations for the treatment of t cell mediated autoimmune diseases
GB8716975D0 (en) Therapeutic agents
GB8701392D0 (en) Therapeutic agents
GB8326602D0 (en) Therapy of human/animal body
IL89953A0 (en) Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
ZA935647B (en) Treatment of sickle cell disease
ZA896422B (en) Use of paf-antagonists for treating autoimmune diseases
AU7695891A (en) Treatment of autoimmune diseases
AU8083591A (en) Therapy and prophylaxis of autoimmune diseases
GB2220652B (en) Treatment of pastures
EP0444931A3 (en) Use of 3-oxygermylpropionic acid to treat and prevent diabetes-dependent autoimmune diseases
IL89431A0 (en) Pharmaceutical compositions for the treatment of autoimmune diseases
JPS57107152A (en) Body implantable therapeutic implement
GB8806116D0 (en) Treatment of skin diseases
GB8722986D0 (en) Preparation of therapeutic agent
SG135193G (en) Therapeutic use of serotonin-antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19910910

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930524

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950829